Shopping Cart
- Remove All
Your shopping cart is currently empty
Anti-LILRB3 Antibody-PE (9J898)
😃Good
Catalog No. TMAY-02186P
Anti-LILRB3 Antibody-PE (9J898) is a PE-conjugated Mouse antibody targeting LILRB3. Anti-LILRB3 Antibody-PE (9J898) can be used in FCM.
Anti-LILRB3 Antibody-PE (9J898)
Anti-LILRB3 Antibody-PE (9J898)
😃Good
Catalog No. TMAY-02186P
Anti-LILRB3 Antibody-PE (9J898) is a PE-conjugated Mouse antibody targeting LILRB3. Anti-LILRB3 Antibody-PE (9J898) can be used in FCM.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 T | $33 | 7-10 days | |
| 100 T | $81 | 7-10 days |
Bulk & Custom
Add to Cart
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
| Description | Antibody Type: Mouse Monoclonal Application: FCM Reactivity: Human |
| Ig Type | Mouse IgG1 |
| Clone | 9J898 |
| Reactivity | Human |
| Verified Activity | Flow cytometric analysis of anti-human GM-CSFRa(CD116) on human peripheral blood monocytes. The fluorescence histograms were derived from events with the forward and side light-scatter characteristics of viable monocytes. |
| Application | FCM |
| Recommended Dose | 5 μl/Test, 0.1 mg/ml |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human LILRB3 (rh LILRB3; TMPY-01682; AAI04994.1; Met1-Glu443) and conjugated with PE under optimum conditions, the unreacted PE was removed. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | PBS solution containing 0.5% BSA and 0.09% sodium azide |
| Research Background | Leukocyte immunoglobulin-like receptor subfamily B member 3, also known as Leukocyte immunoglobulin-like receptor 3, Immunoglobulin-like transcript 5, Monocyte inhibitory receptor HL9, CD85 antigen-like family member A, CD85a and LILRB3, is a single-pass type I membrane protein that belongs to the leukocyte receptor cluster (LRC) present on 19q13.4. LILRB3 / CD85a contains four Ig-like C2-type (immunoglobulin-like) domains. LILRB3 / CD85a contains three copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in the modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases. LILRB3 / CD85a is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found. |
| Conjucates | PE |
| Others Formats | Unconjugated/FITC |
| Antibody Types Available | 3 |
| Immunogen | Recombinant Protein: Human LILRB3 Protein (TMPY-01682) |
| Antigen Species | Human |
| Biology Area | ITIM/ITAM Immunoreceptors and Related Molecules |
Stability & Storage
| Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal. |
| Transport | Shipping with blue ice. |
Sci Citations
Calculator
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . 
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Anti-LILRB3 Antibody-PE (9J898) | purchase Anti-LILRB3 Antibody-PE (9J898) | Anti-LILRB3 Antibody-PE (9J898) cost | order Anti-LILRB3 Antibody-PE (9J898)
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.